Home > Products > Active Pharmaceutical Ingredient (API)

Sinae Active Pharmaceutical Ingredient (API) fabrica, supplementum, Factory

Jiangsu Run'an Pharmaceutical Co, Ltd., subsidiaria omnino possessa de Jiangsu Chiatai Qingjiang Pharmaceutical Co, Ltd., modernus summus tech pharmaceuticus societas specialis in R&D, productionis et venditio fertilitatis ordinandae medicinae et varietatis APIs. Project constructionem mense Novembri 2018 incepit, LIX mu aream obtegens, cum tota obsidione 160 decies Yuan et tota area aedificium 25000 quadratum metrorum.

Praecipua activum medicamentum pharmaceuticum (API) producta: Hydrochloridem Gemcitabinum, Celecoxib, bromhexinum hydrochloridum, Iguratimod, Apremilast, Citrate Tofactinib, Crisaborole, Urapidil Hydrochloride, Sugammadex Natrium, Garlicin, Dexmedetomidine Hydrochloride, Rocuronium Bromidum, Finerenone, etc. elit mundi genus facti et productorum gignentium opificem per constantem emendationem et innovationem in technologiarum, et occasiones praeclarum negotium praebent sodalibus nostris per orbem terrarum. Munus nostrum ad praestantes operas emptores nobis permisit solidas relationes cum sociis nostris toto orbe includere.

View as  
 
CAS NO.1025967-78-5

CAS NO.1025967-78-5

Seres operis nomen: Litalast
Sinensis alias: (S)-2-[2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido]- 3-(3-methanesulfonylphenyl) acidum propionicum ;
Anglicus operis nomen: Lifitegrast
CAS NO.1025967-78-5
Formulae hypotheticae: C29H24Cl2N2O7S
Pondus hypotheticum: 615.4810
Species et possessiones: album ad album-off solid

Lege plusMitte Inquisitionem
CAS 1025967-78-5

CAS 1025967-78-5

Seres operis nomen: Litalast
Sinensis alias: (S)-2-[2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido]- 3-(3-methanesulfonylphenyl) acidum propionicum ;
Anglicus operis nomen: Lifitegrast
CAS 1025967-78-5
Formulae hypotheticae: C29H24Cl2N2O7S
Pondus hypotheticum: 615.4810
Species et possessiones: album ad album-off solid

Lege plusMitte Inquisitionem
1025967-78-5

1025967-78-5

Seres operis nomen: Litalast
Sinensis alias: (S)-2-[2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido]- 3-(3-methanesulfonylphenyl) acidum propionicum ;
Anglicus operis nomen: Lifitegrast
Cas# 1025967-78-5
Formulae hypotheticae: C29H24Cl2N2O7S
Pondus hypotheticum: 615.4810
Species et possessiones: album ad album-off solid

Lege plusMitte Inquisitionem
Lifitegrast API

Lifitegrast API

Seres operis nomen: Litalast
Sinensis alias: (S)-2-[2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido]- 3-(3-methanesulfonylphenyl) acidum propionicum ;
Anglicus operis nomen: Lifitegrast API
Cas# 1025967-78-5
Formulae hypotheticae: C29H24Cl2N2O7S
Pondus hypotheticum: 615.4810
Species et possessiones: album ad album-off solid

Lege plusMitte Inquisitionem
4-Piperidinecarboxylic Acidum

4-Piperidinecarboxylic Acidum

Seres productum nomen, Locally illegal silva
Nomen anglicum: 4-Piperidinecarboxylicum acidum
Cas# 1024828-77-0
Formulae hypotheticae: C36H53N7O6
Pondus hypotheticum: 679.85
Species et possessiones: album ad album-off solid

Lege plusMitte Inquisitionem
1-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl) -4-aminopiperidine-4-acidi carboxylici

1-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl) -4-aminopiperidine-4-acidi carboxylici

Seres productum nomen, Locally illegal silva
Nomen anglicum: Difelikefalin
Cas#1024828-77-0
Formulae hypotheticae: C36H53N7O6
Pondus hypotheticum: 679.85
Species et possessiones: album ad album-off solid
1-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl) -4-aminopiperidine-4-carboxylicum acidum renis longi morbi medicamentum est.

Lege plusMitte Inquisitionem
Quiescere potes ex officina nostra emere Active Pharmaceutical Ingredient (API) in Sinis. Pharmaceutical Run'an professionalis Sinarum Active Pharmaceutical Ingredient (API) fabrica et supplementum, qualitas products alta praebere possumus. Grata res emendas ex officina nostra.
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept